China Universal Asset Management »

Intra Cellular Therapies shares owned by China Universal Asset Management

Quarter-by-quarter ownership of Intra Cellular Therapies (ITCI) shares owned by China Universal Asset Management from 13F filings

Historical chart of China Universal Asset Management investment in Intra Cellular Therapies

Tip: Access up to 7 years of quarterly data

All positions including Intra Cellular Therapies held by China Universal Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Intra Cellular Therapies by China Universal Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $1.3M 19k 69.20
2023-12-31 $797k 11k 71.62
2023-09-30 $128k 2.5k 52.09
2023-06-30 $80k 1.3k 63.32
2023-03-31 $70k 1.3k 54.15
2022-12-31 $51k 962 52.92
2022-09-30 $41k 884 46.38

More positions owned by China Universal Asset Management

Microsoft Corp Common Stock (MSFT)
Nvidia Corp Common Stock (NVDA)
Amazon.com Common Stock (AMZN)
Meta Platforms Inc-class A Common Stock (META)
Vertex Pharmaceuticals Common Stock (VRTX)
Amgen Common Stock (AMGN)
Servicenow Common Stock (NOW)
Gilead Sciences Common Stock (GILD)
Regeneron Pharmaceuticals Common Stock (REGN)
Alphabet Inc-cl A Common Stock (GOOGL)
Adobe Common Stock (ADBE)
Broadcom Common Stock (AVGO)
Visa Inc-class A Shares Common Stock (V)
Apple Common Stock (AAPL)
Uber Technologies Common Stock (UBER)

View all positions for China Universal Asset Management

Top funds holding Intra Cellular Therapies

FMR
Vanguard Group
BlackRock
Daniel D. Thurber
Bellevue Group
venBio Select Advisor
Geode Capital Management
Alliancebernstein
Wellington Management Company
Jpmorgan Chase & Co
ClearBridge Advisors
Franklin Resources
Jennifer Ranahan
T. Rowe Price Associates
Avidity Partners Management

View all funds holding Intra Cellular Therapies